February 9, 2010

ThromboGenics - Positive Microplasmin Phase II data published in Ophthalmology... more »

December 16, 2009

ThromboGenics completes patient enrolment of second Phase III trial of Microplasmin for the non-surgical treatment of eye disease... more »

December 11, 2009

ThromboGenics announces start of Phase II trial of Microplasmin for the treatment of Age-related Macular Degeneration (AMD)... more »

November 18, 2009

ThromboGenics and BioInvent win "Licensing Deal of the Year" at the Scrip Awards 2009... more »

November 17, 2009

ThromboGenics successfully completes private placement... more »

November 16, 2009

ThromboGenics announces private placement... more »

November 16, 2009

ThromboGenics and BioInvent complete Phase I patient trial of anti-PlGF cancer therapeutic TB-403... more »

AACR-NCI-EORTC Conference healthy volunteer results poster - AACR-NCI-EORTC Conference cancer patients results poster

November 4, 2009

ThromboGenics is today issuing a business update for the nine months period ended 30 September 2009... more »

October 28, 2009

ThromboGenics and BioInvent complete patient recruitment of phase II DVT prophylaxis study with Anti-Factor VIII

(TB-402)... more »

October 9, 2009

ThromboGenics raises 0.6 million Euro from the exercise of warrants... more »

October 5, 2009

ThromboGenics announces results from a Phase IIa trial evaluating microplasmin for the treatment of Diabetic Macular Edema... more »

September 24, 2009

ThromboGenics completes patient enrolment in US Phase III Trial of microplasmin for the non-surgical treatment of eye disease... more »

September 11, 2009

ThromboGenics is Shortlisted for “Biotech Company of the Year” and “Licensing Deal of the Year” at Scrip Awards 2009... more »

August 27, 2009
ThromboGenics NV announces business update and half year results 2009... more »

July 3, 2009

ThromboGenics and BioInvent start recruitment of second 100 patient cohort in Phase II study... more »

June 30, 2009

ThromboGenics promoted to the NEXT 150 Index... more »

June 25, 2009

ThromboGenics' Microplasmin phase III program progressing according to schedule... more »

May 14, 2009

ThromboGenics is today issuing a business update for the three month period ended 31 March 2009... more »

May 7, 2009

ThromboGenics raises 3.1 million Euro from the exercise of warrants. more »

March 12, 2009

ThromboGenics announces business update and 2008 full year results...more »

March 6, 2009

ThromboGenics completes patient enrolment for Phase II trial of Microplasmin for the treatment of Diabetic Macular Edema... more »

February 27, 2009

ThromboGenics awarded €3.2 million grant for the development of its anti-VPAC1 antibody for cancer chemotherapy induced thrombocytopenia... more »

February 23, 2009

ThromboGenics and BioInvent start Phase II trial of TB-402, a novel, long acting anticoagulant for Deep Vein Thrombosis (DVT) prophylaxis... more »

January 31, 2009

ThromboGenics’ proprietary cell lines introduced by GenOway in new stem cell production technology... more »

January 26, 2009

ThromboGenics and BioInvent receive technology transfer success fee from Roche for the novel anti-cancer antibody,

TB-403 (Anti-PIGF)... more »

January 9, 2009

ThromboGenics begins Phase III program with Microplasmin for the non-surgical treatment of back of the eye disease

... more »